Complete Summary

TITLE

Cervical cancer: percent of patients screened every 3 years for cervical cancer.

SOURCE(S)

Office of Quality and Performance (10Q). FY2001 VHA performance measurement system. Technical Manual. Washington (DC): Veterans Health Administration (VHA); 2000 Dec 7 [update 2001 Apr 18]. 37 p.

Brief Abstract

DESCRIPTION

This measure assesses the percent of eligible patients screened every 3 years for cervical cancer in primary care settings.

This measure is a component of a composite measure; it can also be used on its own.

RATIONALE

Approximately 16,000 new cases of cervical cancer are diagnosed each year, with about 4,800 deaths annually. The lifetime risk of death from cervical cancer in the United States is 0.3%. Although the 5-year survival rate is about 90% for persons with localized cervical cancer, it is considerably lower (about 14%) for persons with advanced (Stage IV) disease. The incidence of invasive cervical cancer has decreased significantly over the last 40 years, due in large part to early detection programs. Although all sexually active women are at risk for cervical cancer, the disease is more common among women of low socioeconomic status, those with a history of multiple sex partners or early onset of sexual intercourse, and smokers. The incidence of invasive cervical cancer among young white women has increased recently in the United States. Infection with human immunodeficiency virus (HIV) and certain types of human papilloma virus (HPV) also increases the risk of cervical cancer.

Pap test screening is recommended at least every 3 years until age 65 years. Declines in cervical cancer incidence and mortality reported in the United States since the 1950s have been attributed to early detection and treatment of precancerous and cancerous lesions through the use of the Papanicolaou (Pap) test. All women who are or have been sexually active should have regular Pap tests. Testing should begin at the age when the woman first engages in sexual intercourse. Adolescents whose sexual history is thought to be unreliable should be presumed to be sexually active at age 18. There is little evidence that annual

screening achieves better outcomes than screening every 3 years. Pap tests should be performed at least every 3 years. The interval for each patient should be recommended by the physician based on risk factors (e.g. early onset of sexual intercourse, history of multiple sexual partners, low socioeconomic status). Women infected with human immunodeficiency virus require more frequent screening according to established guidelines. There is insufficient evidence to recommend for or against an upper age limit for Pap testing, but recommendations can be made on other grounds to discontinue regular testing after 65 years of age in women who have had regular previous screening with consistently normal results. Women who have undergone a hysterectomy in which the cervix was removed do not require Pap testing, unless the hysterectomy was performed because of cervical cancer or its precursors.

PRIMARY CLINICAL COMPONENT

Cervical cancer; screening

DENOMINATOR DESCRIPTION

The number of female patients with a cervix age less than 65 years seen at least once by a physician (MD or DO), physician assistant (PA), or nurse practitioner (NP) at a specified clinic. Patients who have had a hysterectomy and patients who have a life expectancy that does not lend itself to prevention screening are excluded.

NUMERATOR DESCRIPTION

The number of patients from the denominator screened every 3 years for cervical cancer.

Evidence Supporting the Measure

PRIMARY MEASURE DOMAIN

Process

SECONDARY MEASURE DOMAIN

Not applicable

EVIDENCE SUPPORTING THE MEASURE

A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

Evidence Supporting Need for the Measure

NEED FOR THE MEASURE

Use of this measure to improve performance

EVIDENCE SUPPORTING NEED FOR THE MEASURE

Office of Quality and Performance (10Q). FY2001 VHA performance measurement system. Technical Manual. Washington (DC): Veterans Health Administration (VHA); 2000 Dec 7 [update 2001 Apr 18]. 37 p.

State of Use of the Measure

STATE OF USE

Current routine use

CURRENT USE

External oversight/Veterans Health Administration Internal quality improvement

Application of Measure in its Current Use

CARE SETTING

Ambulatory Care

PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Advanced Practice Nurses Physician Assistants Physicians

LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Single Health Care Delivery Organizations

TARGET POPULATION AGE

Age less than 65 years

TARGET POPULATION GENDER

Female (only)

STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

Characteristics of the Primary Clinical Component

INCIDENCE/PREVALENCE

Approximately 16,000 new cases of cervical cancer are diagnosed each year.

The incidence of invasive cervical cancer has decreased significantly over the last 40 years, due in large part to organized early detection programs.

The incidence of invasive cervical cancer among young white women has increased recently in the United States.

EVIDENCE FOR INCIDENCE/PREVALENCE

U.S. Preventive Services Task Force. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore (MD): Williams & Wilkins; 1996. Screening for cervical cancer. p. 105-117. [113 references]

ASSOCIATION WITH VULNERABLE POPULATIONS

Although all sexually active women are at risk for cervical cancer, the disease is more common among women of low socioeconomic status, those with a history of multiple sex partners or early onset of sexual intercourse, and smokers.

EVIDENCE FOR ASSOCIATION WITH VULNERABLE POPULATIONS

U.S. Preventive Services Task Force. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore (MD): Williams & Wilkins; 1996. Screening for cervical cancer. p. 105-117. [113 references]

BURDEN OF ILLNESS

There are about 4,800 deaths from cervical cancer annually. The lifetime risk of dying from cervical cancer in the United States (U.S.) is 0.3%. Although the 5-year survival rate is about 90% for persons with localized cervical cancer, it is considerably lower (about 14%) for persons with advanced (Stage IV) disease.

EVIDENCE FOR BURDEN OF ILLNESS

U.S. Preventive Services Task Force. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore (MD): Williams & Wilkins; 1996. Screening for cervical cancer. p. 105-117. [113 references]

UTILIZATION

Unspecified

COSTS

Unspecified

Institute of Medicine National Healthcare Quality Report Categories

Staying Healthy

IOM DOMAIN

Effectiveness

Data Collection for the Measure

CASE FINDING

Users of care only

DESCRIPTION OF CASE FINDING

All female patients, age less than 65 years, not already reviewed during the current Fiscal Year with a qualifying visit at one of a specified list of outpatient clinics.

DENOMINATOR (INDEX) EVENT

Encounter

DENOMINATOR INCLUSIONS/EXCLUSIONS

Inclusions

All female patients, age less than 65 years, not already reviewed during the current Fiscal Year with a qualifying visit (refer to the original measure documentation for details) at one of the following 8 outpatient clinics:

- Primary Care
- General Medicine
- Cardiology
- Endocrinology/Metabolism
- Diabetes
- Hypertension
- Pulmonary/Chest
- Women's Clinic

All female patients seen in one of the above clinics and seen by a:

- Physician (MD or DO),
- Physician Assistant (PA), or
- Nurse Practitioner (NP)

All female patients having a life expectancy that lends itself to prevention screening

Exclusions
Prior hysterectomy

Visits at a tertiary facility for a specialty consult only (no other previous primary care or general medicine visit at the tertiary center)

Preventive care screening questions are not applied to certain designated groups of patients included in other samples (see original measure documentation for details).

Any of the following exclude the patient from screening for this prevention measure:

- Documented diagnosis of cancer of the esophagus, liver, or pancreas
- Enrolled in a Veterans Health Administration (VHA) or community-based Hospice program
- Documented in the Medical Record a life expectancy less than 6 months

NUMERATOR INCLUSIONS/EXCLUSIONS

Inclusions

The number of patients from the denominator screened (i.e., evidence of Papsmear performed with interpretation) every 3 years for cervical cancer

Exclusions Unspecified

DENOMINATOR TIME WINDOW

Time window precedes index event

NUMERATOR TIME WINDOW

Fixed time period

DATA SOURCE

Administrative and medical records data

LEVEL OF DETERMINATION OF QUALITY

Individual Case

PRE-EXISTING INSTRUMENT USED

Unspecified

Computation of the Measure

SCORING

Rate

INTERPRETATION OF SCORE

Better quality is associated with a higher score

ALLOWANCE FOR PATIENT FACTORS

Unspecified

STANDARD OF COMPARISON

Internal time comparison Prescriptive standard

PRESCRIPTIVE STANDARD

Fiscal Year (FY) 2001 target for cervical cancer screening component: 90%

EVIDENCE FOR PRESCRIPTIVE STANDARD

Office of Quality and Performance (10Q). FY2001 VHA performance measurement system. Technical Manual. Washington (DC): Veterans Health Administration (VHA); 2000 Dec 7 [update 2001 Apr 18]. 37 p.

Evaluation of Measure Properties

EXTENT OF MEASURE TESTING

Unspecified

Identifying Information

ORIGINAL TITLE

PI - Cervical Cancer Screening.

MEASURE COLLECTION

<u>Fiscal Year (FY) 2001: Veterans Health Administration (VHA) Performance Measurement System</u>

COMPOSITE MEASURE NAME

Prevention Care Index

DEVELOPER

Veterans Health Administration

ADAPTATION

Measure was not adapted from another source.

RELEASE DATE

2001 Dec

REVISION DATE

2001 Apr

MEASURE STATUS

Please note: This measure has been updated. The National Quality Measures Clearinghouse is working to update this summary.

SOURCE(S)

Office of Quality and Performance (10Q). FY2001 VHA performance measurement system. Technical Manual. Washington (DC): Veterans Health Administration (VHA); 2000 Dec 7 [update 2001 Apr 18]. 37 p.

MEASURE AVAILABILITY

The individual measure, "PI - Cervical Cancer Screening," is published in "FY 2001 VHA Performance Measurement System: Technical Manual."

For more information, contact Department of Veterans Affairs, Office of Quality and Performance 10Q, ATTN: Stanlie Daniels, Bonny Collins, and/or Lynnette Nilan. E-mail: stanlie.daniels@hq.med.va.gov or stanlie.daniels@hq.med.va.gov.

NQMC STATUS

This NQMC summary was completed by ECRI on April 18, 2003. The information was verified by the Veterans Health Administration on May 20, 2003.

COPYRIGHT STATEMENT

No copyright restrictions apply.

© 2004 National Quality Measures Clearinghouse

Date Modified: 8/2/2004

FIRSTGOV

